Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 x 109/L to < 100 x 109/L) at baseline: the final analysis of EXPAND

Paola Guglielmelli*, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Francoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire Harrison, Pantelia Roussou, Monika Wroclawska, Divyadeep Karumanchi, Karen Sinclair, Peter A. W. Te Boekhorst, Heinz Gisslinger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)
35 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 x 109/L to < 100 x 109/L) at baseline: the final analysis of EXPAND'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science